FDA panel considers easing peptide restrictions
An FDA advisory panel is reviewing whether to ease restrictions on the compounding of seven experimental peptide therapies. The debate highlights a conflict between the 'Make America Healthy Again' movement and traditional scientific standards regarding safety and clinical evidence.
Why it matters
This meeting represents a significant test of the current administration's influence on federal health policy and the regulation of unproven wellness supplements.
For the latest stories on the science of healthy living, subscribe to NPR's Health newsletter .
A slate of experimental peptide therapies are under scrutiny today in what marks the beginning of a two-day meeting to help determine whether the compounds will become available from specialized pharmacies.
Health RFK Jr. defends his health agenda and Trump's proposed budget cuts in hearing The panel of advisers to the Food and Drug Administration is considering the evidence for seven compounds including some of the most sought-after: TB-500, BPC-157 and MOTs-C.
None of them has undergone the kind of large-scale trials to establish safety and effectiveness that are required for FDA drug approvals.
And yet the therapies have attracted enormous attention in the wellness space. They're promoted for injury recovery, muscle growth and fat loss, skin health, enhancing metabolism and more.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in